Valuation: Verastem, Inc.

Market Cap 530M 463M 427M 394M 742M 51.03B 759M 5.11B 2.01B 24.99B 1.99B 1.95B 86.03B P/E 2026 *
-3.81x
P/E 2027 * -5.38x
Enterprise Value 365M 319M 294M 271M 511M 35.14B 523M 3.52B 1.38B 17.21B 1.37B 1.34B 59.24B EV / Sales 2026 *
3.58x
EV / Sales 2027 * 1.8x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day+4.51%
1 week+9.04%
Current month+57.85%
1 month+46.36%
3 months-8.36%
6 months-9.73%
Current year-21.89%
1 week 5.28
Extreme 5.28
6.07
1 month 3.43
Extreme 3.43
6.07
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
44.98
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/6/26 Sell

Chief Executive Officer

-20,871 0.0339%
22/6/26 Sell

Chief Financial Officer

-4,089 0.0066%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+4.51%+9.04%+16.86%-32.85% 530M
-0.74%-1.74%+54.53%+55.89% 53.83B
-7.17%-4.39%+42.72%+73.70% 52.1B
+0.80%-6.31%+5.62%+413.12% 23.48B
-0.09%-0.01%-16.85%-16.17% 23.13B
+3.46%+2.52%+36.64%-5.41% 19.36B
+0.01%-1.81%+34.32%-32.50% 17.56B
-5.16%-7.00%+168.44%+291.24% 15.2B
+3.62%0.00%+33.47%+643.91% 14.83B
+0.43%-1.03%+25.75%+186.18% 14.06B
Average -0.04%-1.46%+40.15%+157.71% 23.41B
Weighted average by Cap. -1.48%-2.33%+41.20%+137.02%

Financials

2026 *2027 *
Net sales 102M 89.03M 82.15M 75.72M 143M 9.81B 146M 982M 386M 4.8B 383M 374M 16.54B 178M 156M 144M 133M 250M 17.18B 255M 1.72B 676M 8.41B 670M 655M 28.96B
Net income -166M -145M -133M -123M -232M -15.94B -237M -1.6B -628M -7.81B -622M -608M -26.88B -142M -124M -115M -106M -199M -13.68B -203M -1.37B -539M -6.7B -534M -522M -23.07B
Net Debt -165M -144M -133M -123M -231M -15.89B -236M -1.59B -626M -7.78B -620M -606M -26.79B -210M -183M -169M -156M -294M -20.18B -300M -2.02B -795M -9.89B -787M -770M -34.03B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
17/07/26 USD 6.030 +4.51% 3,562,397
16/07/26 USD 5.770 +0.70% 1,985,572
15/07/26 USD 5.730 +2.87% 2,083,595
14/07/26 USD 5.570 +3.72% 3,004,355
13/07/26 USD 5.370 -2.89% 2,417,232
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.030USD
Average target price
15.00USD
Spread / Average Target
+148.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock